ArticleCancer medicine2025
Implementation of a Personalized Risk Model for Lymph Node Metastasis in Endometrial Carcinoma: Healthcare Providers' Perspectives on Use, Barriers, and Facilitators.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe ENDORISK model estimates the risk of lymph node metastases (LNM) in endometrial carcinoma (EC) patients using preoperative clinical variables and biomarkers. This qualitative study investigated healthcare providers' (HCP) perspectives on the use of the model and barriers and facilitators for clinical implementation.
methodsEight focus group interviews were performed among HCPs. A semi-structured interview guide was used based on the Grol and Wensing implementation model.
resultsFocus groups included gynecologists, residents of gynecology, pathologists, radiation oncologists, and a nurse specialist (n = 41). ENDORISK was deemed supportive for counseling of patients and shared decision-making for optimal surgical and adjuvant treatment. Barriers for implementation were difficulty in explaining the model and risk percentages to patients, differences in preoperative diagnostic tools used per hospital, and use of the model with the sentinel node procedure. Facilitators were a clear guideline for using the model with a predefined risk cutoff and making the model easily understandable for patients. A 10% risk cutoff was considered clinically relevant for lymph node assessment.
conclusionHCP found ENDORISK use in clinical practice supportive for patient counseling. Future implementation should focus on a user-friendly interface, a cohesive guideline, and training to aid efficient use and counseling of patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.